Diabetes Health Professional
Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Diabetes Health Reference Charts
Professional Issues Archives
Print | Email | Share | Comments (0)

Amid Accusatory Debate, FDA Puts Black Box Warning on Avandia and Actos


Jul 12, 2007

In a congressional hearing on June 13, 2007, the Food and Drug Administration (FDA) revealed that it has called for a black box warning, the sternest possible, on both Actos and Avandia.

More than a year ago, an FDA drug-safety supervisor recommended that Avandia carry that very warning and was promptly reprimanded for her pains.

After Dr. Nissen's controversial article appeared last month in the New England Journal of Medicine, however, it took the FDA only two days to call for the black box upgrade regarding heart risk.

Throughout the hearing, which was chaired by Democratic Representative Henry Waxman of California, the Democrats criticized the FDA for being lax and the Republicans criticized Dr. Nissen for being inflammatory. Following the contentious meeting, a senior official at GlaxoSmithKline said that the whole issue has been blown out of proportion just so that Democrats can find fault with President Bush's FDA.

During the hearing, a representative of GlaxoSmithKline testified that interim results from the lengthy RECORD trial are reassuring, finding no significant difference in cardiovascular death and heart attack between Avandia takers and control groups.

Apparently both Avandia and Actos are discussing the new warnings with the FDA, in a process that the companies say is supposed to take weeks to months. Since the Nissen report came out last month, Avandia prescriptions have fallen by twenty percent.

Sources: International Herald Tribune
The Wall Street Journal

See "The Latest About Avandia and Actos", August 2007.


Categories: Actos, Food, Heart Care & Heart Disease, Pharmacy, Professional Issues, Type 2 Medications



You May Also Be Interested In...


Click Here To View Or Post Comments

Comments 0 comments - Jul 12, 2007

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.